Key Takeaways Stryker launched Synchfix EVT, a next-gen flexible fixation system for ankle syndesmotic injuries.SYK's device simplifies deployment, supports single-handed use and improves OR efficiency.Stryker's system is first approved for adolescents, expanding reach in ankle trauma care.Stryker (SYK) recently expanded its trauma portfolio with the launch of Synchfix EVT, a next-generation flexible syndesmotic fixation system to improve procedural efficiency and maintain effective ankle stabilization in p ...

Globus Medical (NYSE:GMED) Q4 2025 Earnings call February 24, 2026 04:30 PM ET Speaker10Welcome to Globus Medical's fourth quarter and full year 2025 earnings call. At this time, all lines will be on mute, and a question and answer session will be held after the prepared remarks. I will now turn the call over to Brian Kearns, Senior Vice President of Business Development and Investor Relations. Mr. Kearns, please go ahead.Speaker1Thank you, Dana. Thank you everyone for being with us today. Joining today's c ...

Stryker launches Synchfixâ"¢ EVT, expanding options for flexible syndesmotic fixation [Accessibility Statement] Skip NavigationElevating care with Stryker's next generation device, [Synchfix EVT], which will be featured at the 2026 American College of Foot and Ankle Surgeons (ACFAS) Annual MeetingPORTAGE, Mich., Feb. 24, 2026 /PRNewswire/ -- Stryker (NYSE:SYK), a global leader in medical technologies, announced the launch of Synchfixâ"¢ EVT, its next-generation flexible syndesmotic fixation device designed ...

Core Insights - Stryker (SYK) has launched the T2 Alpha Humerus Nailing System, aimed at simplifying surgical procedures for humeral fracture fixation and enhancing patient care consistency [1][4]. Product Overview - The T2 Alpha Humerus Nailing System improves surgeons' management of complex humeral fractures by providing increased procedural flexibility and builds on Stryker's collaboration with surgeons [2][4]. - The system utilizes Stryker's SOMA technology to manage complex fractures, including non-unions and malunions, featuring an anatomically informed nail design for better alignment and fixation stability [7][10]. - It allows for active intraoperative compression of up to 6 mm for controlled fracture reduction and offers multiplanar screw fixation for enhanced stability [11]. Market Performance - Following the announcement of the new system, SYK shares increased by 0.7%, although the stock has seen a 3.4% decline over the past six months, contrasting with an 11.6% decline in the industry and a 9.8% rise in the S&P 500 during the same period [3]. Long-term Outlook - The launch is expected to strengthen Stryker's trauma and orthopedics portfolio, potentially leading to increased procedure volumes and sustained demand in hospital settings, thereby supporting revenue growth and competitive differentiation in the orthopedic trauma market [4][9]. - The trauma and extremities devices market is projected to reach $16.55 billion by 2026, with a CAGR of 5.2% through 2034, driven by the rising prevalence of orthopedic disorders and advancements in less invasive surgical techniques [12].

Financial Performance - Stryker achieved reported net sales growth of 11.2% in 2025, with net sales totaling $25,116 million[141] - Adjusted net earnings per diluted share increased by 11.8% to $13.63, with net earnings reaching $3,246 million[141] - Net earnings for 2025 increased to $3,246 million or $8.40 per diluted share from $2,993 million or $7.76 per diluted share in 2024[173] - Operating income increased to $4,889 million in 2025, with an operating income margin of 19.5%[163] - Gross profit for 2025 was $16,065 million, up from $14,440 million in 2024, reflecting a gross margin improvement[247] - Net earnings for 2025 were $3,246 million, compared to $2,993 million in 2024, representing an 8.5% growth[247] Sales Growth - MedSurg and Neurotechnology net sales grew by 15.7% as reported, totaling $15,647 million, with a 10.0% increase in constant currency excluding acquisitions[150] - Orthopaedics segment net sales increased by 4.3% to $9,469 million, with a 3.8% increase in constant currency[147] - The United States market contributed $19,006 million in sales, reflecting a 12.2% increase, while international sales reached $6,110 million, an 8.1% increase[147] - MedSurg and Neurotechnology net sales in 2024 increased by 11.1% as reported and 11.6% in constant currency, with a 0.5% negative impact from foreign currency exchange rates[151] - Orthopaedics net sales in 2025 increased by 4.3% as reported and 3.8% in constant currency, with a 0.5% positive impact from foreign currency exchange rates[152] Expenses and Costs - Research, development, and engineering expenses rose to $1,623 million, representing 6.5% of net sales[147] - Selling, general and administrative expenses as a percentage of net sales increased to 34.4% in 2025 from 34.0% in 2024, driven by higher acquisition-related costs[158] - Interest expense increased by 48.4% to $607 million, impacting overall profitability[147] - Cash paid for income taxes in 2025 was $1,002 million, compared to $989 million in 2024, showing a slight increase of 1.3%[260] Capital Allocation and Investments - The company invested $4,960 million in acquisitions and paid $1,284 million in dividends to shareholders in 2025[142] - Stryker's capital allocation strategy continues to prioritize acquisitions, dividends, and share repurchases to drive long-term growth[141] - Cash used in investing activities was $4,866 million in 2025, primarily for the acquisition of Inari and purchases of property, plant, and equipment[191] - Total dividends paid to common shareholders increased to $1,284 million in 2025 from $1,219 million in 2024, with dividends per share rising to $3.36[194] Tax and Impairments - The effective tax rate was 28.1% in 2025, an increase from 14.3% in 2024, influenced by tax effects from intellectual property transfers[171] - Goodwill and other impairments recorded were $170 million in 2025, with significant impairments related to the Spine business in 2024[161] - Adjustments to income taxes for 2025 included a charge of $660 million related to the transfer of intellectual properties between tax jurisdictions[202] - An impairment charge of $273 million was recognized for the Spine reporting unit due to decreased future product demand and increased weighted average cost of capital[221] Liquidity and Financial Position - The company maintained a strong liquidity position with cash, cash equivalents, and marketable securities totaling $4,100 million as of December 31, 2025[195] - Total assets increased to $47,844 million in 2025 from $42,971 million in 2024, representing a growth of 6.5%[251] - Cash and cash equivalents rose to $4,011 million in 2025, compared to $3,652 million in 2024, marking an increase of 9.8%[258] - Long-term debt, excluding current maturities, increased to $14,859 million in 2025 from $12,188 million in 2024, an increase of 21.9%[251] Accounting and Reporting - The company is evaluating the impact of new accounting standards issued by the FASB, including ASU 2025-10 and ASU 2025-07, on its consolidated financial statements[308][309] - The company adopted ASU 2023-09 for income tax disclosures effective January 1, 2025, which may impact future financial reporting[314] - The company performed a quantitative impairment test for goodwill, indicating that the implied fair values of other reporting units exceed their carrying amounts by at least 100%[227] Currency and Derivatives - A hypothetical 10% change in foreign currencies relative to the U.S. Dollar would change the fair value of derivative instruments by approximately $449 million[239] - The company recognized $25 million in cash flow hedges related to cost of sales for 2025, down from $31 million in 2024[335] - The total fair value of cash flow hedges was $148 million, with $15 million in other current assets and ($70) million in other current liabilities[334]

Core Viewpoint - Stryker has launched the T2 Alpha Humerus Nailing System, enhancing surgical workflow and care for complex humeral fractures, while promoting efficiency in hospital settings [1]. Product Features - The T2 Alpha Humerus Nailing System utilizes Stryker's SOMA technology to manage complex humerus fractures, including non-unions and malunions, with a design that aligns with patient anatomy [1][1]. - Key features include guided targeting instrumentation to reduce radiation exposure, multiplanar screw fixation for enhanced stability, and active intraoperative compression of up to 6mm for controlled fracture reduction [1][1][1]. Operational Efficiency - The system simplifies surgical procedures and expands treatment options through intuitive instrumentation, promoting familiarity and consistent workflows across procedures [1][1]. - By integrating with Stryker's existing nailing platform, the system helps streamline training and reduce tray requirements, thereby supporting hospital process efficiencies [1][1]. Company Overview - Stryker is a global leader in medical technologies, impacting over 150 million patients annually through innovative products and services in MedSurg, Neurotechnology, and Orthopaedics [1][1].

Core Insights - Stryker has announced the limited market release of Mako RPS (Robotic Power System) for Total Knee, expanding its Mako robotics platform into a new segment [1][2] - Mako RPS is compatible with Stryker's Triathlon Total Knee System and aims to provide surgeons with the benefits of robotic technology while maintaining the familiarity of manual power tools [2][3] Company Overview - Stryker is a global leader in medical technologies, impacting over 150 million patients annually through innovative products and services in MedSurg, Neurotechnology, and Orthopaedics [5] - The company emphasizes its commitment to advancing orthopaedic patient outcomes through robotics, with nearly 20 years of experience and over 2 million procedures performed globally [3] Product Features - Mako RPS for Total Knee includes intraoperative planning and a robotically enabled saw that utilizes Stryker's patented active adjustment technology, aligning with the surgical plan based on the surgeon's hand movements [3] - The system integrates seamlessly into a surgeon's workflow, providing a familiar cutting experience without the need for cutting blocks, and is designed to work with Stryker's Q Guidance System [3]

Core Insights - Stryker Corporation reported strong fourth-quarter 2025 results with adjusted EPS of $4.47, exceeding estimates and showing an 11.5% year-over-year improvement [1] - The company achieved revenues of $7.17 billion, beating consensus estimates and reflecting an 11.4% year-over-year growth [2] Financial Performance - Adjusted EPS for the full year increased by 11.8% to $13.63, while GAAP EPS rose 8.2% to $8.40 [1] - Revenues for the full year reached $25.1 billion, marking an 11.2% increase year-over-year [2] Revenue Breakdown - U.S. revenues were $5.44 billion, up 11.7% year-over-year, while international sales increased by 10.6% to $1.73 billion [3] - Organic sales growth was driven by a 10.9% increase in unit volume and a 0.1% improvement in prices [2] Segment Analysis - The MedSurg and Neurotechnology segment reported sales of $4.6 billion, up 17.5% year-over-year [5] - Orthopedics segment sales amounted to $2.61 billion, reflecting a 2.2% year-over-year increase [10] Margins and Expenses - Adjusted gross profit was $4.68 billion, up 11.3% year-over-year, with adjusted gross margin at 65.2% [12] - Total operating expenses decreased by 21.4% to $2.82 billion [12] Financial Position - Cash and cash equivalents at the end of the fourth quarter were $4.01 billion, up from $3.26 billion at the end of the previous quarter [14] - Cumulative net cash from operating activities totaled $5.04 billion, compared to $4.24 billion a year ago [14] 2026 Guidance - Stryker expects total revenues to grow between 8-9.5% on an organic basis for 2026, with EPS projected in the range of $14.90 to $15.10 [15] - The Zacks Consensus Estimate for total revenues is $27.23 billion, implying an 8.6% growth [15] Market Position and Growth Drivers - Stryker is positioned for durable growth in global MedTech, driven by robotics adoption and a strong capital cycle [17] - The Mako robotic system's adoption continues to deepen, with over 3,000 systems installed globally [18] - New applications for Mako are set to launch in mid-2026, expanding the addressable market [19] Pricing and Margin Outlook - Management anticipates pricing improvements in 2026 similar to those in 2025, with new product launches potentially at higher price points [20] - Stryker expects to expand margins despite a $400 million tariff headwind in 2026 [21]

Core Insights - Stryker reported revenue of $7.17 billion for the quarter ended December 2025, reflecting an 11.4% increase year-over-year and surpassing the Zacks Consensus Estimate of $7.13 billion by 0.61% [1] - The company's EPS was $4.47, up from $4.01 in the same quarter last year, exceeding the consensus estimate of $4.40 by 1.71% [1] Financial Performance - International net sales reached $1.73 billion, slightly above the average estimate of $1.72 billion, marking a year-over-year increase of 10.7% [4] - U.S. net sales were reported at $5.44 billion, matching the average estimate and showing an 11.7% increase year-over-year [4] - MedSurg and Neurotechnology sales totaled $4.56 billion, exceeding the estimated $4.53 billion, with a significant year-over-year growth of 17.5% [4] Segment Analysis - Orthopaedics sales amounted to $2.61 billion, aligning with estimates and reflecting a 2.2% year-over-year increase [4] - Within Orthopaedics, hips sales were $499 million, slightly below the estimated $504.79 million, but still showing a 7.8% increase year-over-year [4] - Trauma and Extremities sales were $1.09 billion, below the estimated $1.1 billion, with a year-over-year growth of 9% [4] Key Metrics - Stryker's stock has returned 1.8% over the past month, outperforming the Zacks S&P 500 composite's 0.8% change [3] - The company holds a Zacks Rank 3 (Hold), indicating expected performance in line with the broader market [3]

Group 1 - The core viewpoint is that Stryker, a medical equipment maker, has raised its full-year profit forecast due to strong sales of its implants and other medical devices [1] Group 2 - The company is experiencing robust demand for its products, which is contributing to the positive outlook for the year [1] - The increase in profit forecast indicates confidence in the company's growth trajectory within the medical device industry [1]